Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
The Behavioral and Brain Sciences|July 5, 2026
A missing piece of the puzzle? Applying the peer culture concept to the study of human cultural originsWilliam Daniel Snyder, Elisa Bandini
Chest|November 8, 2020
Curious Case of Unexplained Dyspnea With MalignancySrinadh Annangi, Daniel Snyder, Kevin Smith
Scientific Reports|December 15, 2022
The method of exclusion (still) cannot identify specific mechanisms of cultural inheritanceAlberto Acerbi, William Daniel Snyder, Claudio Tennie
Biological Theory|November 1, 2021
Clarifying Misconceptions of the Zone of Latent Solutions Hypothesis: A Response to Haidle and Schlaudt: Miriam Noël Haidle and Oliver Schlaudt: Where Does Cumulative Culture Begin? A Plea for a Sociologically Informed Perspective (Biological Theory 15: 161-174, 2020)Elisa Bandini, Jonathan Scott Reeves, William Daniel Snyder, et al.
Substance Use & Misuse|September 12, 2022
The Overdose Crisis and Using Alone: Perspectives of People Who Use Drugs in Rural and Semi-Urban Areas of British ColumbiaSaranee Fernando, Jennifer Hawkins, Marinel Kniseley, et al.
Plos One|December 3, 2019
Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistanceRavi K Patel, Mark C Weir, Kexin Shen, et al.
Toxins|February 21, 2019
Correction: Field, M. et al. AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in PatientsMalgorzata Field, Andrew Splevins, Philippe Picaut, et al.
Toxins|December 16, 2018
AbobotulinumtoxinA (Dysport<sup>®</sup>), OnabotulinumtoxinA (Botox<sup>®</sup>), and IncobotulinumtoxinA (Xeomin<sup>®</sup>) Neurotoxin Content and Potential Implications for Duration of Response in PatientsMalgorzata Field, Andrew Splevins, Philippe Picaut, et al.
The International Journal of Neuroscience|January 19, 2018
A 500 U/2 mL dilution of abobotulinumtoxinA vs. placebo: randomized study in cervical dystoniaMark F Lew, Allison Brashear, Khashayar Dashtipour, et al.
Advances in Therapy|March 23, 2024
Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims AnalysisBenjamin Chastek, Adam Carrera, Christina Landis, et al.
Pageof 3